The genetics services company, which is backed by Alphabet, Illumina, WuXi PharmaTech and Johnson and Johnson, has now raised more than $490m altogether.

23andMe, the US-based genetics services provider backed by corporate investors including internet and technology conglomerate Alphabet, secured $250m yesterday in a round led by venture capital firm Sequoia Capital.

Financial services group Fidelity Management & Research (FMR) also took part in the round, as did family office Euclidean Capital, investment firms Altimeter Capital and Casdin Capital, and research support organisation Wallenberg Foundation.

The funding was raised at a $1.5bn pre-money valuation, according to a TechCrunch report last week, and 23andMe…